| Autor: |
Dijkstra, Madelon, Kuiper, Babette I., Schulz, Hannah H., van der Lei, Susan, Puijk, Robbert S., Vos, Danielle J. W., Timmer, Florentine E. F., Scheffer, Hester J., Buffart, Tineke E., van den Tol, M. Petrousjka, Lissenberg-Witte, Birgit I., Swijnenburg, Rutger-Jan, Versteeg, Kathelijn S., Meijerink, Martijn R. |
| Předmět: |
|
| Zdroj: |
CardioVascular & Interventional Radiology; Feb2024, Vol. 47 Issue 2, p253-262, 10p |
| Abstrakt: |
Purpose: The objective of the COLLISION RELAPSE trial is to prove or disprove superiority of neoadjuvant systemic therapy followed by repeat local treatment (either thermal ablation and/or surgical resection), compared to repeat local treatment alone, in patients with at least one recurrent locally treatable CRLM within one year and no extrahepatic disease. Methods: A total of 360 patients will be included in this phase III, multicentre randomized controlled trial. The primary endpoint is overall survival. Secondary endpoints are distant progression-free survival, local tumour progression-free survival analysed per patient and per tumour, systemic therapy-related toxicity, procedural morbidity and mortality, length of hospital stay, pain assessment and quality of life, cost-effectiveness ratio and quality-adjusted life years. Discussion: If the addition of neoadjuvant systemic therapy to repeat local treatment of CRLM proves to be superior compared to repeat local treatment alone, this may lead to a prolonged life expectancy and increased disease-free survival at the cost of possible systemic therapy-related side effects. Level of Evidence: Level 1, phase III randomized controlled trial. Trial Registration: NCT05861505. May 17, 2023. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink